ICVB 1042
Alternative Names: ICVB-1042; IOV-1042Latest Information Update: 06 Jul 2023
At a glance
- Originator IconOVir Bio
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 02 Jun 2023 Pharmacodynamics data from a preclinical trials in Solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 24 May 2023 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT05904236)
- 14 Apr 2023 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)